Optimal Tailored Screening Protocol after Living Donor Liver Transplantation for Hepatocellular Carcinoma

The indication for hepatocellular carcinoma (HCC) is expanding in living donor liver transplantation (LDLT). Early detection and effective management of recurrence has become an important issue in LDLT for HCC. This study aimed to find an optimal screening protocol in terms of screening interval and...

Full description

Bibliographic Details
Main Authors: Park, Min-Su, Lee, Kwang-Woong, Yi, Nam-Joon, Choi, Young Rok, Kim, Hyeyoung, Hong, Geun, Suh, Kyung-Suk, Kwon, Choon-Hyuck David, Joh, Jae-Won, Lee, Suk-Koo
Format: Online
Language:English
Published: The Korean Academy of Medical Sciences 2014
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4214935/
id pubmed-4214935
recordtype oai_dc
spelling pubmed-42149352014-11-03 Optimal Tailored Screening Protocol after Living Donor Liver Transplantation for Hepatocellular Carcinoma Park, Min-Su Lee, Kwang-Woong Yi, Nam-Joon Choi, Young Rok Kim, Hyeyoung Hong, Geun Suh, Kyung-Suk Kwon, Choon-Hyuck David Joh, Jae-Won Lee, Suk-Koo Original Article The indication for hepatocellular carcinoma (HCC) is expanding in living donor liver transplantation (LDLT). Early detection and effective management of recurrence has become an important issue in LDLT for HCC. This study aimed to find an optimal screening protocol in terms of screening interval and screening tools by analyzing recurrence pattern after LDLT for HCC. A total of 205 LDLT patients in two centers from February 1999 to October 2010 was reviewed. Recurrence appeared in 55 cases. Six risk factors for recurrence were identified: preoperative alpha-fetoprotein >400, Edmonson grade 3 or 4, tumor size >7 cm, tumor number ≥7, minimal tumor necrosis in the transarterial chemoembolization group and positive micro-vascular invasion. Four groups with different ranges of index scores showed different recurrence-free survival and median time to recurrence. Group I showed low and late recurrence. Groups II and III showed linearly increased rate of recurrence until 18 months. Group IV showed very early recurrence within 6 months. Across the groups, extra-hepatic recurrence developed in more than 40% of cases and multi-organ recurrence rate was 20%. The screening interval should be different based on the risk of recurrence. Screening should include work-up for extra-hepatic recurrence as well as intra-hepatic recurrence. The Korean Academy of Medical Sciences 2014-10 2014-10-08 /pmc/articles/PMC4214935/ /pubmed/25368488 http://dx.doi.org/10.3346/jkms.2014.29.10.1360 Text en © 2014 The Korean Academy of Medical Sciences. http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
repository_type Open Access Journal
institution_category Foreign Institution
institution US National Center for Biotechnology Information
building NCBI PubMed
collection Online Access
language English
format Online
author Park, Min-Su
Lee, Kwang-Woong
Yi, Nam-Joon
Choi, Young Rok
Kim, Hyeyoung
Hong, Geun
Suh, Kyung-Suk
Kwon, Choon-Hyuck David
Joh, Jae-Won
Lee, Suk-Koo
spellingShingle Park, Min-Su
Lee, Kwang-Woong
Yi, Nam-Joon
Choi, Young Rok
Kim, Hyeyoung
Hong, Geun
Suh, Kyung-Suk
Kwon, Choon-Hyuck David
Joh, Jae-Won
Lee, Suk-Koo
Optimal Tailored Screening Protocol after Living Donor Liver Transplantation for Hepatocellular Carcinoma
author_facet Park, Min-Su
Lee, Kwang-Woong
Yi, Nam-Joon
Choi, Young Rok
Kim, Hyeyoung
Hong, Geun
Suh, Kyung-Suk
Kwon, Choon-Hyuck David
Joh, Jae-Won
Lee, Suk-Koo
author_sort Park, Min-Su
title Optimal Tailored Screening Protocol after Living Donor Liver Transplantation for Hepatocellular Carcinoma
title_short Optimal Tailored Screening Protocol after Living Donor Liver Transplantation for Hepatocellular Carcinoma
title_full Optimal Tailored Screening Protocol after Living Donor Liver Transplantation for Hepatocellular Carcinoma
title_fullStr Optimal Tailored Screening Protocol after Living Donor Liver Transplantation for Hepatocellular Carcinoma
title_full_unstemmed Optimal Tailored Screening Protocol after Living Donor Liver Transplantation for Hepatocellular Carcinoma
title_sort optimal tailored screening protocol after living donor liver transplantation for hepatocellular carcinoma
description The indication for hepatocellular carcinoma (HCC) is expanding in living donor liver transplantation (LDLT). Early detection and effective management of recurrence has become an important issue in LDLT for HCC. This study aimed to find an optimal screening protocol in terms of screening interval and screening tools by analyzing recurrence pattern after LDLT for HCC. A total of 205 LDLT patients in two centers from February 1999 to October 2010 was reviewed. Recurrence appeared in 55 cases. Six risk factors for recurrence were identified: preoperative alpha-fetoprotein >400, Edmonson grade 3 or 4, tumor size >7 cm, tumor number ≥7, minimal tumor necrosis in the transarterial chemoembolization group and positive micro-vascular invasion. Four groups with different ranges of index scores showed different recurrence-free survival and median time to recurrence. Group I showed low and late recurrence. Groups II and III showed linearly increased rate of recurrence until 18 months. Group IV showed very early recurrence within 6 months. Across the groups, extra-hepatic recurrence developed in more than 40% of cases and multi-organ recurrence rate was 20%. The screening interval should be different based on the risk of recurrence. Screening should include work-up for extra-hepatic recurrence as well as intra-hepatic recurrence.
publisher The Korean Academy of Medical Sciences
publishDate 2014
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4214935/
_version_ 1613150621061349376